Group 1: Goodman Group (GMG) - Goodman Group's share price has decreased approximately 5.9% since the beginning of 2025, making it the largest ASX-listed property group in 2025 with operations across multiple continents including Australia, New Zealand, the UK, Japan, the US, and Brazil [1] - The company specializes in warehouses, large-scale logistics facilities, and business and office parks, aiming to build long-term relationships with customers and deliver high-quality assets [2] - The current dividend yield for Goodman Group shares is around 0.88%, which is lower than its 5-year average of 1.28%, indicating a potential decline in dividends or an increase in share price [6] Group 2: Sonic Healthcare (SHL) - Sonic Healthcare, listed in April 1987, is one of the largest pathology businesses globally, with operations in Australia, New Zealand, Europe, and North America, offering services such as laboratory medicine, pathology, diagnostic imaging, and corporate medical services [3][4] - The current price-sales ratio for Sonic Healthcare shares is 1.19x, which is below its 5-year long-term average of 1.94x, suggesting that SHL shares may be undervalued [7] - Sonic Healthcare focuses on acting in the best interests of doctors and patients, striving for medical excellence and being a desirable workplace [4]

Investment Ratings - ResMed (RMD AU) is rated Overweight (OW) with a price target of A$45.00 [24][30] - Sonic Healthcare (SHL AU) is rated Neutral (N) with a price target of A$29.00 [30][32] Core Insights - ResMed is expected to benefit from rising awareness of obstructive sleep apnoea, leading to increased demand for CPAP treatments [2][12] - Sonic Healthcare faces funding pressures that are likely to undermine its margin expansion potential [6][15] Summary by Sections ResMed - **Earnings Growth**: ResMed's earnings are projected to be approximately 5% ahead of consensus due to expected gross margin improvements and stronger revenue growth [4][12] - **Margin Expansion**: The company is on track to achieve further gross margin increases supported by production efficiency and favorable currency movements [3][24] - **Valuation**: ResMed trades at a 23x FY26E PE, which is below its historical average, indicating potential undervaluation [5][24] Sonic Healthcare - **Funding Pressures**: Sonic Healthcare is experiencing reimbursement pressures in key markets, particularly Germany and Australia, which are expected to negatively impact revenues [6][10] - **US Operations**: The US business has underperformed, and challenges are anticipated to persist in 2025 [7][9] - **Long-term Margin Decline**: Sonic's pathology margins have been in long-term decline, attributed to expansion into lower-margin markets and a tight funding environment [10][15]